
Jan 12 (Reuters) - Amgen AMGN.O said on Monday a 24-week study of monthly doses of its experimental obesity drug MariTide in people with type 2 diabetes showed "robust and clinically meaningful" reduction in both blood sugar and weight.
In a 52-week extension study, a large majority of participants who received a lower monthly dose or a quarterly dose maintained the weight loss achieved during the initial phase 2 trial, the company said.